Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Prolonged Administration of Naxitamab with Irinotecan and Temozolomide for the Treatment of Relapsed or Refractory Neuroblastoma

Trial Status: active

This phase I trial studies the side effects and best infusion time of naxitamab when given together with irinotecan and temozolomide in treating patients with neuroblastoma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Naxitamab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Irinotecan is in a class of antineoplastic medications called topoisomerase I inhibitors. It blocks a certain enzyme needed for cell division and deoxyribonucleic acid (DNA) repair and may kill tumor cells. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Giving naxitamab infusions over 3-5 hours (prolonged) with irinotecan and temozolomide may be safe, tolerable, and/or effective in treating patients with relapsed or refractory neuroblastoma.